BRKR reports Q1 earnings above expectations and expects organic revenue growth in Q2 amid improving order trends.
Bruker (NASDAQ:BRKR) reported stronger-than-expected Q1 earnings, driven by robust order momentum in semiconductor metrology and overseas academic and government markets. The company offset weakness in U.S. academic funding, achieving a book-to-bill ratio above 1.0 for three consecutive quarters.
Organic revenue declined in Q1 due to tough comparisons and softness in China and U.S. government spending. However, management expects growth to resume in Q2, citing strong demand for AI-related semiconductor tools and new fab capacity. China remains a long-term opportunity despite local competition.
Semiconductor metrology and diagnostics lines led the recovery, with management highlighting structural growth potential in these segments. The company’s outlook reflects improving demand trends across key markets.